Introgen Therapeutics Reports Results for the Third Quarter of Fiscal 2001
(PR Newswire)...Introgen is also conducting a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer.......New applications using INGN 201 to stimulate the human immune system to attack tumor cells are being explored.......INGN 241 (Adenoviral-mda7), for the treatment of solid tumors, is in Phase I clinical development....- May 01 4:00 PM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010501/datu057.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines